Table of Contents

October 2012, Volume 19, Number 5

Editorial

    • Wouter W de Herder and
    • Charis Eng

    Obesity, diabetes mellitus, and cancer

    Endocr Relat Cancer 19 (5) E5-E7, doi:10.1530/ERC-12-0264

Focus Review

    • Manami Inoue and
    • Shoichiro Tsugane

    Insulin resistance and cancer: epidemiological evidence

    Endocr Relat Cancer 19 (5) F1-F8, doi:10.1530/ERC-12-0142 first published on 31 July 2012
    • YunFeng Cui and
    • Dana K Andersen

    Diabetes and pancreatic cancer

    Endocr Relat Cancer 19 (5) F9-F26, doi:10.1530/ERC-12-0105 first published on 27 July 2012
    • Dara Hope Cohen and
    • Derek LeRoith

    Obesity, type 2 diabetes, and cancer: the insulin and IGF connection

    Endocr Relat Cancer 19 (5) F27-F45, doi:10.1530/ERC-11-0374 first published on 16 May 2012
    • Mathis Grossmann and
    • Gary Wittert

    Androgens, diabetes and prostate cancer

    Endocr Relat Cancer 19 (5) F47-F62, doi:10.1530/ERC-12-0067 first published on 18 April 2012
    • Aimee J Varewijck and
    • Joseph A M J L Janssen

    Insulin and its analogues and their affinities for the IGF1 receptor

    Endocr Relat Cancer 19 (5) F63-F75, doi:10.1530/ERC-12-0026 first published on 14 March 2012
    • Roman Vangoitsenhoven,
    • Chantal Mathieu,
    • and Bart Van der Schueren

    GLP1 and cancer: friend or foe?

    Endocr Relat Cancer 19 (5) F77-F88, doi:10.1530/ERC-12-0111 first published on 12 June 2012

Review

    • Andrea Frilling,
    • Goran Åkerström,
    • Massimo Falconi,
    • Marianne Pavel,
    • Jose Ramos,
    • Mark Kidd,
    • and Irvin Mark Modlin

    Neuroendocrine tumor disease: an evolving landscape

    Endocr Relat Cancer 19 (5) R163-R185, doi:10.1530/ERC-12-0024 first published on 29 May 2012

Article

    • Jennifer A Chan,
    • David P Ryan,
    • Andrew X Zhu,
    • Thomas A Abrams,
    • Brian M Wolpin,
    • Paige Malinowski,
    • Eileen M Regan,
    • Charles S Fuchs,
    • and Matthew H Kulke

    Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors

    Endocr Relat Cancer 19 (5) 615-623, doi:10.1530/ERC-11-0382 first published on 26 June 2012
    • Nicola M Bougen,
    • Michael Steiner,
    • Mikhail Pertziger,
    • Arindam Banerjee,
    • Severine E Brunet-Dunand,
    • Tao Zhu,
    • Peter E Lobie,
    • and Jo K Perry

    Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells

    Endocr Relat Cancer 19 (5) 625-644, doi:10.1530/ERC-12-0042 first published on 17 July 2012
    • Trinh Trung Hieu,
    • Anthony W Russell,
    • Ross Cuneo,
    • Justin Clark,
    • Tomas Kron,
    • Per Hall,
    • and Suhail A R Doi

    Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis

    Endocr Relat Cancer 19 (5) 645-655, doi:10.1530/ERC-12-0176 first published on 31 July 2012
    • Larry K Kvols,
    • Kjell E Oberg,
    • Thomas M O'Dorisio,
    • Pharis Mohideen,
    • Wouter W de Herder,
    • Rudolf Arnold,
    • Ke Hu,
    • Yilong Zhang,
    • Gareth Hughes,
    • Lowell Anthony,
    • and Bertram Wiedenmann

    Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

    Endocr Relat Cancer 19 (5) 657-666, doi:10.1530/ERC-11-0367 first published on 17 July 2012
    • Muhammad Yasir Asghar,
    • Tero Viitanen,
    • Kati Kemppainen,
    • and Kid Törnquist

    Sphingosine 1-phosphate and human ether-a′-go-go-related gene potassium channels modulate migration in human anaplastic thyroid cancer cells

    Endocr Relat Cancer 19 (5) 667-680, doi:10.1530/ERC-12-0092 first published on 13 August 2012
    • Xinying Li,
    • Zhiming Wang,
    • Jianming Liu,
    • Cane Tang,
    • Chaojun Duan,
    • and Cui Li

    Proteomic analysis of differentially expressed proteins in normal human thyroid cells transfected with PPFP

    Endocr Relat Cancer 19 (5) 681-694, doi:10.1530/ERC-12-0156 first published on 17 August 2012
    • Roberto Bellelli,
    • Maria Domenica Castellone,
    • Ginesa Garcia-Rostan,
    • Clara Ugolini,
    • Carmelo Nucera,
    • Peter M Sadow,
    • Tito Claudio Nappi,
    • Paolo Salerno,
    • Maria Carmela Cantisani,
    • Fulvio Basolo,
    • Tomas Alvarez Gago,
    • Giuliana Salvatore,
    • and Massimo Santoro

    FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma

    Endocr Relat Cancer 19 (5) 695-710, doi:10.1530/ERC-12-0031 first published on 23 August 2012
    • Nan Liu,
    • Sheng Tai,
    • Boxiao Ding,
    • Ryan K Thor,
    • Sunita Bhuta,
    • Yin Sun,
    • and Jiaoti Huang

    Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis

    Endocr Relat Cancer 19 (5) 711-723, doi:10.1530/ERC-12-0150 first published on 23 August 2012
    • Takeshi Sasaki,
    • Takehisa Onishi,
    • and Akira Hoshina

    Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer

    Endocr Relat Cancer 19 (5) 725-730, doi:10.1530/ERC-12-0133 first published on 17 July 2012
|

This Issue

October 2012; 19 (5)
Cover
  1. Editorial
  2. Focus Review
  3. Review
  4. Article

Find articles in this issue containing these words:

New Articles: issue in progress

  1. June 2018, 25 (6)
  1. Alert me to new issues of Endocrine-Related Cancer

Most